Core Set of Patient-Reported Outcome Measures for Measuring Quality of Life in Clinical Obesity Care
- PMID: 39008218
- PMCID: PMC11289183
- DOI: 10.1007/s11695-024-07381-4
Core Set of Patient-Reported Outcome Measures for Measuring Quality of Life in Clinical Obesity Care
Abstract
Purpose: The focus of measuring success in obesity treatment is shifting from weight loss to patients' health and quality of life. The objective of this study was to select a core set of patient-reported outcomes and patient-reported outcome measures to be used in clinical obesity care.
Materials and methods: The Standardizing Quality of Life in Obesity Treatment III, face-to-face hybrid consensus meeting, including people living with obesity as well as healthcare providers, was held in Maastricht, the Netherlands, in 2022. It was preceded by two prior multinational consensus meetings and a systematic review.
Results: The meeting was attended by 27 participants, representing twelve countries from five continents. The participants included healthcare providers, such as surgeons, endocrinologists, dietitians, psychologists, researchers, and people living with obesity, most of whom were involved in patient representative networks. Three patient-reported outcome measures (patient-reported outcomes) were selected: the Impact of Weight on Quality of Life-Lite (self-esteem) measure, the BODY-Q (physical function, physical symptoms, psychological function, social function, eating behavior, and body image), and the Quality of Life for Obesity Surgery questionnaire (excess skin). No patient-reported outcome measure was selected for stigma.
Conclusion: A core set of patient-reported outcomes and patient-reported outcome measures for measuring quality of life in clinical obesity care is established incorporating patients' and experts' opinions. This set should be used as a minimum for measuring quality of life in routine clinical practice. It is essential that individual patient-reported outcome measure scores are shared with people living with obesity in order to enhance patient engagement and shared decision-making.
Keywords: Bariatric surgery; Clinical practice; Obesity treatment; Outcome reporting; Patient-reported outcome measures; Patient-reported outcomes; Quality of life.
© 2024. The Author(s).
Conflict of interest statement
Claire E. E. de Vries and Valerie M. Monpellier founded the S.Q.O.T. initiative. The initiative was cofounded by Bart A. van Wagensveld, Ignace M. C. Janssen, and Ronald S. L. Liem. Phillip J Dijkhorst joined the board of the S.Q.O.T. initiative in 2021. Claire E. E. de Vries, Ronald S. L. Liem, and Lotte Poulsen were involved in developing the eating scales in the BODY-Q. Claire E.E. de Vries and Ronald S. L. Liem are members of the organizing committee and were not permitted to participate in, nor influence, discussions during the S.Q.O.T. consensus meetings or the voting rounds. Lotte Poulsen was not permitted to participate in the voting rounds if the BODY-Q was available for a specific patient-reported outcome domain. None of the aforementioned persons received financial compensation for developing the BODY-Q or for any other BODY-Q-related activity. Ignace M. C. Janssen was a consultant at Johnson & Johnson and the Dutch Obesity Clinic. Johan Ottosson previously sat on the advisory board of Novo Nordisk. The University of Leeds received payments for Professor Halford’s work on ACTION-Teens. Over the last 3 years, Stuart W. Flint reported research grants from the National Institute for Health Research, the Office of Health Improvement & Disparities, Public Health England, Doncaster Council, West Yorkshire Combined Authority, Johnson & Johnson, Novo Nordisk, and the University of Leeds. He reported receiving personal fees from the Royal College of General Practitioners and institutional fees from Public Health England, and he received funding to attend meetings at the parliament of the UK, Novo Nordisk, Johnson & Johnson, and Safefood. Stuart W. Flint also reported unpaid roles with Obesity UK. Bruno Halpern sat on the advisory boards of Novo Nordisk, Lilly, and Astra Zeneca. Additionally, he received lecture fees from Novo Nordisk, Astra Zeneca, Merck, and Abbott Nutrition. Furthermore, BH conducted clinical trials in collaboration with Novo Nordisk, Lilly, and Boehringer Ingelheim. John B. Dixon was a consultant at and sat on the advisory boards of Nestle Health Science and Reshape Lifesciences. He also sat on the advisory boards and also received speaker fees from Novo Nordisk and Lilly.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
